Market Overview

REGENXBIO to Present at Upcoming Investor Conferences


ROCKVILLE, Md., Nov. 5, 2020 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the following November investor conferences, which will each be held in a virtual meeting format:

29th Annual Credit Suisse Virtual Healthcare Conference
Date: Thursday, November 12, 2020
Presentation: Thursday, November 12, 2020 at 8:45 a.m. ET

Barclays Gene Editing & Gene Therapy Summit
Date: Monday, November 16, 2020
Presentation: Monday, November 16, 2020 at 2:00 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO's website at An archived replay of each webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.


REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.


Tricia Truehart
Investor Relations and Corporate Communications

Eleanor Barisser, 212-600-1902

David Rosen, 212-600-1902

(PRNewsfoto/REGENXBIO Inc.)


Cision View original content to download multimedia:


View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at